Try our Advanced Search for more refined results
Life Sciences - June, 2015
312 articles
- Indirect Buyers Decertified In Wellbutrin Pay-For-Delay Suit
- Apotex To Pay AstraZeneca $98M For Prilosec IP Infringement
- Kaye Scholer Brings 2 Corporate Partners From Katten
- Pharma, Medical Device Cos. Paid $6.5B To Doctors In 2014
- Amarin Not Backing Down In Free Speech Suit Against FDA
- Purdue Halts FDA Review Of Abuse-Resistant OxyContin Label
- Nexium Buyers Say 3rd Circ.'s Lamictal Ruling Backs New Trial
- US Demands Up To $3.35B From Novartis In FCA Suit
- New HHS OIG Unit To Specialize In Fines, Exclusions
- The Playful, Plainspoken Prose Of Justice Elena Kagan
- Justice Thomas Lets His Dissents Do The Talking
- FTC, Fla. Sue Lifewatch For Telemarketing Abuse On Elderly
- Calif. Gov. Signs Law Limiting Vaccination Exemptions
- Cephalon Hit With Latest Pay-For-Delay Generic Provigil Row
- How Drug Cos. Can Minimize Risks Of 'Right To Try' Laws
- Your Advance Conflict Waiver May Be A Conflict Creator
- An 'Exceptional Case' One Year After Octane: Part 1
- The 15 Biggest High Court Decisions Of The Past 15 Years
- Boutiques Wipe The Supreme Court Floor With BigLaw Rivals
- Supreme Court Ends Term Sharply Divided
- Justices Pen More Dissents To Show Votes Aren't Political
- Janssen Ignored Nerve Damage Risk Of Levaquin, Suit Claims
- Three Justices Trusted With Most Controversial Opinions
- Justices Won't Hear Athena's Appeal In Eyelash Product Suit
- Celgene Forms $1B Collaboration With Juno Therapeutics
- FDA Must Cough Up Gilead Hep C Docs, Health Groups Say
- Top 15 High Court Class Action Rulings Of The Past 15 Years
- Corporate Attys Want More High Court Action After Slow Term
- Recent Rulings Shed Light On Fed. Circ's Approach To Teva
- Honigman Scores Ex-Takeda IP Counsel, Paul Hastings Atty
- Goodwin Guides AMAG's $700M Buy Of Stem Cell Bank
- Post-Grant Challenges In Life Sciences: A Midyear Assessment
- Rescue Remedy Maker Pares Down False Ad Class Action
- 3rd Circ. Ruling Isn't Last Word On Noncash Pay-For-Delay
- Bristol-Myers Inks 208K-SF Mass. Lease With REIT Alexandria
- Medtronic Gets Doc's Heart Valve Patent Nixed In AIA Review
- Ex-OtisMed CEO Gets 2 Years For Illegally Shipping Devices
- 5 IPOs Look To Raise $677M Before Long Holiday Weekend
- Medtronic Calls For Gray Reed To Be Forced Off Patent Suit
- Provigil Buyers Ask Judge To Reconsider Class Cert. Denial
- AbbVie Fights FTC's Quick Appeal Bid In Pay-For-Delay Case
- Tyco Faces Leaner Suit Over Eli Lilly Warehouse Heist
- Kythera Investor Challenges $2B Sale To Allergan
- 3rd Circ. Says Cash Not Key For Pay-For-Delay Suits
- The Top 3 New Do's And Don'ts For Law Firm Websites
- Grooming Lessons For Biotech From Abercrombie & Fitch
- FDA Warns Noven's ADHD Patch Can Cause Skin Disfiguration
- FDA Panel To Mull Essure Implant Safety Amid Death Reports
- Brazil Fines Eli Lilly $11.8M For Sham Patent Litigation
- Zoloft Plaintiffs Want Pfizer Expert Booted For Retractions
- Calif. Lawmakers OK Law Ending Vaccination Exemption
- Deals Rumor Mill: Valeant, Zoetis, Aetna, Total
- Not So Fast-Track: More Work To Do In TPP Talks
- Supplement Co. Says Atty Hid Info On Class Rep
- NLRB Clears Fresenius' Firing Of Vulgar Pro-Union Worker
- VC-Backed Glaukos Beats Expectations With $108M IPO
- PE-Backed Diagnostic Imaging Co. Lantheus Misses IPO Target
- 4 Life Science Innovations That Give Life To Patent Growth
- Allergan Says Venture Fund's AIA Petition Is 'Extortion'
- Your Future Tech Clients Would Like A Word With You
- Blue Cross Accuses Boehringer, Teva Of Pay-For-Delay Deal
- House Committee OKs $153B HHS, Labor, Ed Spending Bill
- Drug Cos. Escape Suit Claiming They Inflated Eye Drop Doses
- Pharmacies, Patients Ask 3rd Circ. For Fees In ERISA Case
- 9th Circ. Nixes Class In False Ad Suit Over Nutrition Drink
- Bluebird Stock Offering Lands $500M To Fund Drug Pipeline
- Ferring Sues Actavis Over Generic Blood Loss Drug
- Kirkland Fights DQ Recommendation In Teva Takeover Bid
- Zimmer's $14B Biomet Buy Completed After FTC Gives The OK
- Insolvent Aussie Pharma Sued Over Painkiller's Flop
- Glaucoma Implant Maker Glaukos Boosts IPO Target
- Chinese Medical Equipment Lessor Seeks $546M In HK IPO
- 11th Circ. Doesn't Corral Small-Dollar Class Actions
- The Global Hot Spots Of 2015
- Law360 Reveals The Global 20 Firms Of 2015
- The 5 Firms That Made The Biggest Global Gains
- Ambitious Global Firms Must Have Roots In These Cities
- FDA Goes On Offense In Amarin's Free Speech Suit
- Branch Law Firm Says Arbitration Args Taken Out Of Context
- TTAB Overturns Rejection Of Eli Lilly Diabetes Product Mark
- Hagens Berman, Grunenthal To Settle Time-Barred Suits
- Fed. Circ. Says Pfizer's Celebrex IP Double-Patented
- Sheller Can't Show Injury In Risperdal Fight, FDA Says
- Novartis Hit With Gleevec Sham Litigation Class Action
- OIG Targets Part D Fraud One Week After National Sweep
- Calif. Attys Can Rep Marijuana Dispensaries, SF Bar Says
- Allergan Pulled 'Hard Switch' To Block Generics, Unions Say
- Congress Has To Beat The Clock For 21st Century Cures Act
- Calif. High Court's Cipro Decision Is Problematic
- Abbott Accused Of Withholding Docs In Whistleblower Suit
- High Court Rejects Appeal Over Patent Maintenance Fees
- Australian Gene Therapy Biotech Benitec Eyes $70M US IPO
- Expert Must Show Docs In Reed Smith Atty Paxil Suicide Suit
- FCC Asked To Lift Ultra-Wideband Restrictions
- AbbVie Fights FTC Discovery Expansion In Pay-For-Delay Suit
- CVC-Led Group Picks Up Controlling Alvogen Stake
- Conkwest Looks To Draw $173M In Latest Cancer-Focused IPO
- High Court Won't Review Inequitable Conduct Standards
- McGuireWoods Nabs Real Estate Pro To Grow London Office
- Prenatal Diagnostics Co. Natera Sets Terms For $100M IPO
- Utah — The Latest Battleground In Resale Price Maintenance
- Merck Nixes Some Actions in Vioxx Securities Fraud Battle
- GNC Again Dodges Class Action Over Health Supplement Ads
- Roxane Can Fix Arguments In Jazz's Xyrem Patent Suit
- FDA Patent Rule Has Brands, Generics In War Of Words
- Taxation With Representation: Wachtell, Latham, Cravath
- Deals Rumor Mill: Martha Stewart Living, Synlab, Novolex
- Egenix Gets Nod For $4M Auction Led by Stalking Horse
- MDL Judge Urged To Move Ethicon, Bard Mesh Suits To Philly
- Pneumonia Drug Developer Nabriva Eyes $92M IPO
- Teva Takes Mylan Stake Amid Takeover Dispute
- Biz Software Co. Mindbody Hits Target With $100.1M IPO
- Insights Into HRSA's Proposed 340B Program Rule
- A New Drug Pricing Environment In China
- Why Lateral Candidacies Fail
- FDA Finalizes Controversial Policies On Pill Shapes, Sizes
- Considering Drug Policies After Colo. High Court Ruling
- One Year After Alice: Was It The Right Medicine?
- ClearCorrect Gets USPTO To Re-Examine Invisalign Patents
- Fed. Circ. Axes Teva MS Drug Patent In High Court Remand
- In $700M DOJ Sweep, Medicare Part D Fraud Stands Out
- FDA Targets Counterfeit Drug Websites In Global Sweep
- Hundreds Charged In $712M Medicare Fraud Sweep
- 2 Minority Views From The Top Of BigLaw
- Custom Joint Co. ConforMIS Prepares For Up To $144M IPO
- House Passes Bill To Repeal ACA Medical Device Tax
- Lumenis Ltd. To Be Acquired By XIO In $510M Buyout
- Canada Unveils Proposed IP Competition Guidelines
- Judge OKs $1.2B Cephalon Deal In FTC Pay-For-Delay Suit
- Inspire Pharma Pays $5.9M To End FCA Suit Over Eye Drug
- La. Appeals Court Backs Novartis In Schizophrenia Drug Suit
- M&A Stokes Red-Hot Life Sciences IPO Market
- Where Do We Stand One Year After Alice?
- Blank Rome Adds Former Surgeon As IP Partner In New York
- Insulet Hit With Securities Suit Over Insulin Pump Claims
- Ex-NFL Player Can't Revisit Pump-And-Dump Verdict
- FTC Pushes 1st Circ. To Revive Loestrin Pay-For-Delay Suit
- Fed. Circ. Backs Celgene Win In Teva Cancer Drug Patent Suit
- Botox Maker Allergan Pays $2.1B For Aesthetics Co. Kythera
- Hill-Rom To Pay $2B For Medical Device Maker Welch Allyn
- New China FDA Guidance May Speed Up Device Approvals
- Mayo Test Dooms Breakthrough Biotech Invention
- 3rd Circ. Reiterates ERISA Allows 'Catalyst Theory' Fees
- Abbott Backs Mylan In Takeover Woes
- Voices Of The Bar: Meet The IP Experts
- AAI, Profs Push 1st Circ. To Overturn Pay-For-Delay Ruling
- Deals Rumor Mill: Houlihan Lokey, NCR, Coty
- Liberty Medical Makes Push For Ch. 11 Plan Confirmation
- Design Defect Claims Go Forward in Ethicon Mesh MDL
- Calif. Judge Boots Last Suit In Accutane Litigation
- Microbiome Biotech Seres Sets Terms For $106M IPO
- $17B Merck-Sigma Deal Gets EU Nod After Antitrust Fixes
- Diagnostics Co. Lantheus Seeks $83M In Revived IPO
- The High Court's Impact On Drug Disposal Ordinances
- 16 Cos. Polish $2.8B In IPO Plans
- 10th Circ. Lifts Injunction On Utah Contact Lens Pricing Law
- Even Breakthrough Patents Can Be Invalid, Sequenom Shows
- Bayer Downplays IUD Birth Control Safety Risks, Suit Claims
- Calif. Court Upholds Medtronic Spinal Fusion Suit Transfer
- J&J Attys, Witnesses Can't Reveal Own Tylenol Use: Plaintiffs
- Generic-Drug Makers Urge Changes To User-Fee Law
- Home Depot, GNC Among 25 Sued Over Site Search Patent
- Cohen Seglias Merges With Thaler Liebeler Amid DC Launch
- Gilead Defective Drug FCA Suit Tossed For Second Time
- Trustee Cut From J&J Heir's Tax Case Against Proskauer Rose
- J&J Can't Escape False Ad Suit Over 'Natural' Sweetener
- Plaintiffs Say Expert Overcomes Objections In Zoloft MDL
- Allergan Seeks 3rd Circ. Take On 'Critical' FCA Questions
- Tips To Avoid Conflicts When Hiring In-House Lawyers
- Glaucoma Device Maker Glaukos Sets Terms For $80M IPO
- Fried Frank, Dechert Guide CVS' $1.9B Target Pharmacy Buy
- Belgian Biotech Celyad Targets $99M US IPO
- Dish Worker's Firing For Medical Pot Use Deemed Lawful
- Is UK Pharmacy Legislation A Step Forward?
- Tech, Biotech Take Center Stage As 10 IPOs Target $1.6B
- Patient Wins $4.5M In First Wright Hip Implant Trial
- Pa. Zoloft Verdict Dims Plaintiffs' Hopes In MDL Expert Row
- India Fines GSK, Sanofi $10M For Anti-Competitive Plot
- Medical Device Co. Invuity Hits Slashed Terms In $48M IPO
- McKesson Nabs $6B DOD Pharmaceutical Deal Extension
- Pfizer Fights To Keep Expert In Zoloft Birth Defect MDL
- Teva Gets Nod For $24M Nexium Pay-For-Delay Settlement
- Judge Warns Axiom To Fix Fees Bid In Trademark Spat
- Amarin Decision Opens Door To Longer Exclusivity Periods
- Fed. Circ. Nixes Fetal DNA Test Patent Under Myriad, Mayo
- Why Law Firms Collapse
- Big Pharma Torches FDA In Amarin's Free Speech Suit
- Protein Powder Co. Says It Meets FDA Rules In False Ad Case
- Branch Law Firm Waived Fee Arbitration, Houston Court Hears
- Provigil Antitrust Cert. Bid Doomed By Inability To ID Class
- Health Care-Focused Joint Venture Lands $192M For 1st Fund
- Prosensa Investors Urge Redo On Suit Over Failed Drug
- Deals Rumor Mill: Apollo, GE, Alstom, Novartis
- Melinta Raises $67M In Venture Capital For New Drug
- Parkinson's-Focused Biotie's US IPO Hits Increased Target
- Philly Jury Clears Pfizer In 2nd Zoloft Birth Defect Case
- Dementia Drugmaker Axovant Draws $315M In Upsize IPO
- Goldwater Sues FDA For Access To Ebola Drug Docs
- 8 Product-Hopping Takeaways From Namenda Ruling
- Fed. Circ. Says Judge Erred In Defining Kaneka IP Claims
- Bayer Gets Preliminary Nod For $4.5M Cipro Antitrust Deal
- 1st Circ. Told Not To Focus On Cash In Loestrin Pay-For-Delay
- Vermont, German Ski Equipment Cos. In Patent Row
- Bayer Sells Diabetes Unit For $1B To Panasonic
- Intec Becomes Latest Parkinson's Drug Maker To Eye IPO
- Darvocet Failure To Warn Mass Action Transferred To Ky.
- Zoloft Birth Defect Case Heads To Philly Jury
- IRS, Ex-Employees Blast Liberty Medical's Ch. 11 Plan
- Teva Trades Kirkland For Sullivan & Cromwell In Mylan Bid
- Olympus Convinces PTAB To Nix 2 Electrosurgery Patents
- China Biologic Nabs $315M In Upsized Follow-On Offering
- First Databank Escapes Ranbaxy's Acne Med Libel Suit
- Covington Snags Pharmaceutical Policy Adviser
- Medical Marijuana And Gaming: How Close Is Too Close?
- Judge Recommends Blocking Kirkland From Repping Teva
- Axis Needn't Defend Advertising Co. In Fraud Suit: Judge
- Eli Lilly Pushes To Toss Cymbalta Withdrawal Suits
- Medtronic Escapes 3 Shareholder Suits Over Infuse Device
- 2nd Circ. Boots Medtronic Infuse Suit For Overstepping FDA
- Bayer Must Face FCA Claims Over Off-Label Trasylol Marketing
- Brokers Plead Guilty To Insider Trading In Ardea Biosciences
- JPML Centralizes Contact Lens Antitrust Actions In Florida
- Groups Tell 4th Circ. Bard Evidence Was Rightly Excluded
- Newman Can't Save Investors In SEC Insider Trading Case
- DC Circ. Upholds FTC's Pharma Patent Rules
- Actavis, Others Plotted To Delay Generic Namenda, Suit Says
- Is Your Pharmacy Ready For Drug Supply Chain Integrity?
- Bohai Pharma Hit With Suit Claiming Securities Shenanigans
- BioScrip Can't Hide Behind Omnicare In Securities Suit
- FDA Looks To Placate Amarin, Duck Free Speech Decision
- FDA Panel To Further Examine Amgen Cholesterol Drug
- Sex Bias Plaintiffs Fight Merck's Bid For Depositions
- Mom Says She'd Have Stopped Zoloft If Warned Of Risks
- Pfizer Plaintiffs Defend Robbins Geller Fees In $400M Deal
- Hedge Fund Hits Another Horizon Patent With AIA Review Bid
- FTC, Bayer Duel As Probiotics Promo Trial Nears
- Drug Development Service Patheon Eyes $100M US IPO
- FTC Asks For Quick Appeal Of AbbVie Pay-For-Delay Defeat
- Patent Applicants, Overlook Enablement At Your Peril
- 9th Circ. Says Alphatec Securities Action Was Weak
- FDA Panel To Give New Sanofi Cholestrol Drug A Closer Look
- Where Pay-For-Delay Stands 2 Years After Actavis
- NIH Suspends Drugmaking Facility After Fungal Contamination
- Actavis Asks 2nd Circ. To Rehear Namenda Antitrust Case
- Squire Patton Boggs Snags Ex-Fish & Richardson Principal
- Full Fed. Circ. Won't Review $61M Enzo Patent Ruling
- June IPO Market Chugs Forward As 6 Cos. Target $500M
- Cook Group Scores Win In Pelvic Mesh Suit
- Zoloft Caused Baby's Heart Defect, Expert Tells Philly Jury
- Standing Snafu Sinks Prosthetic Patent Row, Fed. Circ. Says
- A-Rod's Cousin Gets 7 Mos. For Role In MLB Doping Scandal
- Merck Whistleblowers Demand More Info On Mumps Vaccine
- Globus Fights J&J Unit's $16M Patent Win At Fed. Circ.
- EndoChoice Draws $95M In IPO At Low End Of Range
- Illumina Makes Arbitration Plea In IP Row Over DNA Testing
- Cardinal Health Pays $1.1B For Generics Distributor
- Congress' Bipartisan Revival Opens Health Policy Doors
- Calif. Ruling Backs Actos Pay-For-Delay Suit, Buyers Say
- The Rise Of Companion Diagnostics In Personalized Medicine
- CR Bard Gets Medical Implant Liability Suit Trimmed
- FDA Advisers Back Sprout's Drug To Boost Female Sex Drive
- European Biotechs Catch US IPO Fever
- CR Bard Gets Mesh Implant Suit Trimmed
- Nexium Buyers Say Namenda Ruling Supports Injunction Bid
- Greenberg Traurig Guides Opko In $1.47B Buy For Lab Co.
- AbbVie Rips 'Unsound' FDA Stand On Biosimilar Labels
- Mayer Brown Lures Food And Drug Partner From Jones Day
- Patent Dance Takes Center Stage In Amgen V. Sandoz Appeal
- Not All Claim Constructions Get Teva Deference: Fed. Circ.
- Cephalon Must Face Most Of FCA Off-Label Marketing Suit
- Catalent's PE Backers Draw $406M In Secondary Offering
- Puma Hit With Stock Drop Suit Over Breast Cancer Drug
- Boston Scientific Wants To Ax $34M Pelvic Mesh Judgment
- WHO Herbicide Cancer Study Worries US Corn, Soy Industries
- Amgen Says ACA Requires Sandoz To Disclose Biosimilar Info
- Teva, Others Seek To Nix Retailers' Pay-For-Delay Suits
- SEC, Feds Charge 4 Men For $4M Insider Trading Scheme
- Cystic Fibrosis Drugmaker Nivalis Sets Terms For $64M IPO
- 4th Circ. Told To Uphold $2M Bard Mesh Bellwether Verdict
- Class Tries Again For Cert. In Cymbalta Withdrawal Suit
- Health Plans Lose Provigil Pay-For-Delay Class Cert Bid
- Dendreon Gets Nod For Ch. 11 Liquidation Plan
- New FDA Rule Curbs Antibiotic Use In Animals
- Orrick Adds Ex-Davis Polk Atty Who Advised On Pandora IPO
- Pfizer Came Up Short On Zoloft Warnings, Expert Says
- Honigman Opens In Chicago With Schopf & Weiss Merger
- Alaska AG Wants To Ax Lupin Pay-For-Delay Probe Challenge
- AGs Urge FDA To Improve Dietary Supplement Regulation
- CytRx Settles Investor Claims Over 'Spring-Loaded' Options
- Prenatal Diagnostics Co. Natera Eyes $100M IPO
- House Committee Targets FDA's 'Untitled Letter' Discipline
- Prometheus Pushes Fed. Circ. To Revive IBS Drug Patent
- States Want In On New Charges Against Novartis In Exjade Suit
- 5 Insights From Schneider Electric GC Peter Wexler
- House Tax Panel Approves Medical Device Tax Repeal Bill
- Your Trademark Could Be A False Advertisement
- Sheller Tries To Stop FDA Bid To End Risperdal Doc Suit
- Wright Hip Implant Faulty, Jury Told In First Of 1,200 Cases
- Ethicon Severs Malpractice Claims From Pelvic Mesh Suit
- Fla. Compounding Pharmacy Pays $3.8M To Settle FCA Suit
- Surgical Lighting Device Co. Invuity Sets $73.6M IPO Terms
- Mylan Slams Teva For 'Playing Games' With Takeover Bid
- Novartis Sues Apotex Over Planned Zometa Generic
- Tyco's ANDA Suit Against Mutual Was Legit, Court Finds
- FDA Signals Tougher Approach To Animal Drug Compounding
- FCC Wants Feedback On Endo, AEP Fax Rule Waiver Requests
- Zoloft Caused Heart Defects In Newborn, Philly Jury Hears
- Merck Prevails In Former Exec's Pregnancy Bias Suit
- Hiscock, Damon Morey Merge Into Upstate NY's Largest Firm
- Philips Didn't Interfere With Worker's Other Job, 6th Circ. Says
- Axovant Sciences Sets Terms For $269M IPO
- PE-Backed 3SBio Seeks $711M In Hong Kong IPO